Boston Scientific (NYSE:BSX) beat Wall Street’s earnings expectations by 6 cents despite posting a 25 percent profit decline.
Natick, Mass.-based BSX reported profits of $142 million, or 9 cents per diluted share, on sales of $1.87 billion for the three months ended Sept. 30. That compares with profits of $190 million, or 12 cents diluted EPS, on sales of $1.92 billion during the same period last year.